Ablynx NV [Euronext Brussels and Nasdaq: ABLX] today announced additional results from the Phase III HERCULES study with caplacizumab, the Company’s anti-von Willebrand factor (vWF) …
Roche has announced that the Phase III IMmotion151 study met its co-primary endpoint of investigator-assessed progression-free survival (PFS) and demonstrated that the combination of Tecentriq® …
Bayer and Nektar Therapeutics’ experimental inhaled antibiotic has failed to hit key targets assessing its effect on survival in patients with Gram-negative pneumonia. The Phase …
TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop …
Ablynx NV [Euronext Brussels and Nasdaq: ABLX] has announced that results from its Phase III HERCULES study of caplacizumab have been selected as one of only six …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
